Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. [electronic resource]
Producer: 20130816Description: 2447-54 p. digitalISSN:- 1097-0142
- Adenocarcinoma -- chemistry
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- analysis
- Body Mass Index
- Breast Neoplasms -- chemistry
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Lymphatic Metastasis
- Middle Aged
- Receptor, ErbB-2 -- analysis
- Receptors, Estrogen -- analysis
- Receptors, Progesterone -- analysis
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.